Clinical trials: Retinal Detachment
Pigment Epithelial Detachment
iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
LT1009-Oph-002 is a Phase 1b study designed to evaluate the safety and potential efficacy of iSONEP following one, two or three injections of iSONEP, as needed, for the treatment of Pigment Epithelial Detachment (PED) secondary…
- Trial name
- PED (NCT01334255)
- Testing
- iSONEP (sonepcizumab/LT1009)
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Lpath, Inc.
Diabetic Retinopathy, Posterior Vitreous Detachment
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
The purpose of this study is to assess the efficacy and safety of up to 3 intravitreal injections of ocriplasmin (0.0625mg or 0.125mg), in subjects with moderate to very severe non-proliferative diabetic retinopathy (NPDR), to…
- Conditions
- Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
- Trial name
- CIRCLE (NCT02681809)
- Testing
- ocriplasmin 0.0625mg, ocriplasmin 0.125mg
- Where
- 38 sites in United States, Czechia and 7 more
- Volunteers
- 48 people
- Sponsor
- ThromboGenics
Rhegmatogenous Macula-off Retinal Detachment
Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function
This study will evaluate the efficacy and safety of the Brimo PS DDS® Applicator System (200 μg and 400 μg brimonidine tartrate) on visual function in patients with previous rhegmatogenous macula-off retinal detachment.
- Trial name
- NCT00972374
- Testing
- 400 ug Brimonidine Implant, 200 ug Brimonidine Implant
- Where
- 6 sites in United States, India and 4 more
- Volunteers
- 44 people
- Sponsor
- Allergan
Proliferative Vitreoretinopathy
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy.
- Trial name
- NCT04136366
- Testing
- ADX-2191 (intravitreal methotrexate 0.8%), Standard surgical care procedure
- Where
- 23 sites in United States
- Volunteers
- 106 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Rhegmatogenous Retinal Detachment - Macula Off
Acute Retinal Detachment Repair With the iSeelr™ Retinal Detachment Repair System
This study is a first-in-human clinical trial testing a new treatment for rhegmatogenous retinal detachments. The new treatment called retinal thermofusion uses a special laser device called iSeelr™ during surgery.
- Trial name
- NCT06468397
- Testing
- iSeelr™
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Photofuse Pty Ltd
Retinitis Pigmentosa, Macula Off
Transcorneal Electrical Stimulation Therapy for Retinal Disease
Transcorneal stimulation may enable neurons to survive degeneration processes via enhanced secretion of neurotrophic substances and direct stimulation of neurons.
- Conditions
- Retinitis Pigmentosa, Macula Off, Primary Open Angle Glaucoma, Hereditary Macular Degeneration
- Trial name
- NCT00804102
- Testing
- Transcorneal Electrical Stimulation, DTL-electrode attached without energy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Okuvision GmbH
Retinal Pigment Epithelial Detachment With Vascularization, Age Related Macular Degeneration
Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration
This is a pilot, single-center, interventional clinical trial in which subjects will receive 16 Gy of IRay treatment and Lucentis, followed by Lucentis treatment as needed.
- Trial name
- NCT01521819
- Testing
- Iray, Lucentis
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Oraya Therapeutics, Inc.